Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genocea Biosciences (GNCA)

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,249
  • Shares Outstanding, K 26,149
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,810 K
  • 60-Month Beta 2.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.39
  • Low Estimate -0.56
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.38 +9.66%
on 10/10/19
3.58 -27.09%
on 09/19/19
-0.97 (-27.09%)
since 09/18/19
3-Month
2.38 +9.66%
on 10/10/19
3.86 -32.30%
on 07/24/19
-1.05 (-28.69%)
since 07/18/19
52-Week
2.24 +16.52%
on 12/31/18
11.28 -76.86%
on 06/03/19
-3.31 (-55.91%)
since 10/18/18

Most Recent Stories

More News
Genocea to Host Third Quarter 2019 Corporate Update Conference Call & Webcast

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2019 financial results and corporate update conference...

GNCA : 2.61 (-1.14%)
Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

Additional positive GEN-009 clinical immunogenicity data driven by ATLAS(TM) to be presented at ESMO

GNCA : 2.61 (-1.14%)
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX : 95.78 (-1.10%)
GNCA : 2.61 (-1.14%)
REPH : 12.18 (+0.50%)
ZTS : 128.12 (-0.27%)
CPRX : 5.24 (-1.04%)
FLXN : 14.24 (-1.25%)
VRCA : 14.65 (-1.81%)
Genocea to Present at September Healthcare Conferences

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present...

GNCA : 2.61 (-1.14%)
Genocea Biosciences: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $6.5 million in its second quarter.

GNCA : 2.61 (-1.14%)
Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results

Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009;

GNCA : 2.61 (-1.14%)
Genocea to Host Quarterly Corporate Update Conference Call & Webcast on July 25th at 8:30 am ET

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its second-quarter 2019 financial results and corporate update conference...

GNCA : 2.61 (-1.14%)
Hercules Capital Announces Multiple Portfolio Company Achievements in Q2 2019

Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture growth stage companies backed by some of the leading U.S. and...

TCDA : 35.40 (+1.35%)
INSM : 17.42 (-0.63%)
AVEO : 0.91 (-1.22%)
GNCA : 2.61 (-1.14%)
MYOV : 5.05 (-8.84%)
AQ : 13.24 (unch)
MRVL : 23.68 (+0.21%)
VICL : 0.68 (-15.68%)
PINS : 25.31 (-2.62%)
TMDX : 17.74 (-2.58%)
FSLY : 22.70 (-3.24%)
HTGC : 13.44 (-0.81%)
HCXZ : 25.68 (-0.27%)
HCXY : 25.95 (-0.77%)
Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the pricing of its previously announced underwritten public offering...

GNCA : 2.61 (-1.14%)
Thinking about buying stock in Aurora Cannabis, Cypress Semiconductor, Delmar Pharmaceuticals, Genocea Biosciences, or Stellar Biotech?

InvestorsObserver issues critical PriceWatch Alerts for ACB, CY, DMPI, GNCA, and SBOT.

ACBFF : 8.6900 (-12.80%)
CY : 23.44 (-0.04%)
GNCA : 2.61 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade GNCA with:

Business Summary

Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections,...

See More

Key Turning Points

2nd Resistance Point 2.75
1st Resistance Point 2.68
Last Price 2.61
1st Support Level 2.55
2nd Support Level 2.49

See More

52-Week High 11.28
Fibonacci 61.8% 7.83
Fibonacci 50% 6.76
Fibonacci 38.2% 5.69
Last Price 2.61
52-Week Low 2.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar